Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing antiHIV1 monoclonal antibodies bNAbs given to HIV1 exposed uninfected neonates and infants study protocol for a phase I trial

Abstract

Description

Keywords

Citation

WOS

Endorsement

Review

Supplemented By

Referenced By